ATE502035T1 - 2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung - Google Patents

2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung

Info

Publication number
ATE502035T1
ATE502035T1 AT05809089T AT05809089T ATE502035T1 AT E502035 T1 ATE502035 T1 AT E502035T1 AT 05809089 T AT05809089 T AT 05809089T AT 05809089 T AT05809089 T AT 05809089T AT E502035 T1 ATE502035 T1 AT E502035T1
Authority
AT
Austria
Prior art keywords
amido
preparation
therapeutic use
phenylthiazole derivatives
phenylthiazole
Prior art date
Application number
AT05809089T
Other languages
English (en)
Inventor
Pierre Casellas
Daniel Floutard
Pierre Fraisse
Samir Jegham
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE502035T1 publication Critical patent/ATE502035T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT05809089T 2004-10-19 2005-10-17 2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung ATE502035T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0411083A FR2876692B1 (fr) 2004-10-19 2004-10-19 Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
PCT/FR2005/002565 WO2006042954A1 (fr) 2004-10-19 2005-10-17 Dérivés de 2-amido-4-phenylthiazole, leur préparation et leur application en thérapeutique

Publications (1)

Publication Number Publication Date
ATE502035T1 true ATE502035T1 (de) 2011-04-15

Family

ID=34950743

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05809089T ATE502035T1 (de) 2004-10-19 2005-10-17 2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung

Country Status (27)

Country Link
US (1) US7598392B2 (de)
EP (1) EP1807421B1 (de)
JP (1) JP2008517042A (de)
KR (1) KR20070085395A (de)
CN (1) CN101065376A (de)
AR (1) AR051334A1 (de)
AT (1) ATE502035T1 (de)
AU (1) AU2005296958A1 (de)
BR (1) BRPI0518231A2 (de)
CA (1) CA2584774A1 (de)
DE (1) DE602005026964D1 (de)
EA (1) EA200700901A1 (de)
EC (1) ECSP077402A (de)
FR (1) FR2876692B1 (de)
GT (1) GT200500292A (de)
IL (1) IL182624A0 (de)
MA (1) MA29017B1 (de)
MX (1) MX2007004740A (de)
NO (1) NO20072515L (de)
PA (1) PA8649901A1 (de)
PE (1) PE20060585A1 (de)
SV (1) SV2006002274A (de)
TN (1) TNSN07145A1 (de)
TW (1) TW200630364A (de)
UY (1) UY29169A1 (de)
WO (1) WO2006042954A1 (de)
ZA (1) ZA200703876B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2854158B1 (fr) 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
FR2872813B1 (fr) 2004-07-09 2007-01-19 Sanofi Synthelabo Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
WO2007070600A2 (en) 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(5-membered heteroaromatic ring)-amido anti-viral compounds
FR2895989B1 (fr) 2006-01-06 2010-04-30 Sanofi Aventis Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
WO2009076404A1 (en) * 2007-12-10 2009-06-18 Epix Delaware, Inc. Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
BRPI0820701A2 (pt) * 2007-12-11 2015-06-16 Cytopathfinder Inc Composto de carboxamida e seu uso como agonistas do receptor de quimiocina
TW201006832A (en) * 2008-07-15 2010-02-16 Novartis Ag Organic compounds
CN102264227B (zh) * 2008-12-22 2014-07-23 凯莫森特里克斯股份有限公司 C5aR拮抗剂
WO2012093101A1 (en) 2011-01-04 2012-07-12 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
WO2014002053A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
US9487483B2 (en) 2012-06-28 2016-11-08 Novartis Ag Complement pathway modulators and uses thereof
ES2647124T3 (es) 2012-06-28 2017-12-19 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
JP6154897B2 (ja) 2012-06-28 2017-06-28 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
EP2867226B1 (de) 2012-06-28 2018-11-14 Novartis AG Modulatoren des komplementweges und verwendungen davon
JP6238980B2 (ja) 2012-07-12 2017-11-29 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
AU2021230289A1 (en) 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
CN118019739A (zh) 2021-08-25 2024-05-10 皮克医疗公司 Eif4e抑制剂及其用途
JP2024534127A (ja) 2021-08-25 2024-09-18 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用
KR20240140019A (ko) * 2023-03-15 2024-09-24 현대약품 주식회사 신규한 화합물, 및 이를 포함하는 약학적 조성물
WO2026054614A1 (ko) * 2024-09-09 2026-03-12 현대약품 주식회사 신규한 화합물, 및 이를 포함하는 약학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2146898A (en) * 1937-12-06 1939-02-14 Int Harvester Co Potato digger
FR2406634A1 (fr) * 1977-10-19 1979-05-18 Fabre Sa Pierre Immunostimulants derives d'amino thiazoles
FR2677356B1 (fr) 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
WO1993000342A1 (en) 1991-06-21 1993-01-07 Boehringer Mannheim Italia S.P.A. 2-amino-4-aryl-thiazoles with antiasthmatic and anti-inflammatory activities on the respiratory tract
US6506751B1 (en) 1999-11-12 2003-01-14 Millennium Pharmaceuticals, Inc. Thiazolidinone compounds useful as chemokine inhibitors
US6797820B2 (en) * 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
US6852752B2 (en) * 1999-12-17 2005-02-08 Vicuron Pharmaceuticals Inc. Urea compounds, compositions and methods of use and preparation
EP1344525A4 (de) * 2000-12-22 2005-05-25 Ishihara Sangyo Kaisha Anilinderivate oder ihre salze und diese enthaltende zytokinproduktion-inhibitoren
US7265134B2 (en) 2001-08-17 2007-09-04 Merck & Co., Inc. Tyrosine kinase inhibitors
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
FR2854158B1 (fr) * 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
TW200423931A (en) 2003-04-30 2004-11-16 Hoffmann La Roche Novel aniline derivatives, their manufacture and use as pharmaceutical agents
FR2872813B1 (fr) 2004-07-09 2007-01-19 Sanofi Synthelabo Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
US7906645B2 (en) 2004-12-24 2011-03-15 Astrazeneca Ab Heterocyclic compounds as ccr2b antagonists
FR2895989B1 (fr) 2006-01-06 2010-04-30 Sanofi Aventis Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
IL182624A0 (en) 2007-07-24
UY29169A1 (es) 2006-05-31
DE602005026964D1 (de) 2011-04-28
US20070259847A1 (en) 2007-11-08
SV2006002274A (es) 2006-06-28
TNSN07145A1 (fr) 2008-11-21
EA200700901A1 (ru) 2007-10-26
FR2876692A1 (fr) 2006-04-21
JP2008517042A (ja) 2008-05-22
BRPI0518231A2 (pt) 2008-11-11
EP1807421B1 (de) 2011-03-16
NO20072515L (no) 2007-06-28
WO2006042954A8 (fr) 2008-03-13
AR051334A1 (es) 2007-01-03
KR20070085395A (ko) 2007-08-27
AU2005296958A1 (en) 2006-04-27
TW200630364A (en) 2006-09-01
CA2584774A1 (fr) 2006-04-27
MX2007004740A (es) 2007-06-18
US7598392B2 (en) 2009-10-06
PE20060585A1 (es) 2006-08-18
PA8649901A1 (es) 2006-06-02
MA29017B1 (fr) 2007-11-01
GT200500292A (es) 2006-05-11
CN101065376A (zh) 2007-10-31
ECSP077402A (es) 2007-05-30
WO2006042954A1 (fr) 2006-04-27
EP1807421A1 (de) 2007-07-18
FR2876692B1 (fr) 2007-02-23
ZA200703876B (en) 2008-12-31

Similar Documents

Publication Publication Date Title
ATE467633T1 (de) 2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung
ATE395342T1 (de) 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
DE502005002105D1 (de) 4-benzimidazol-2-yl-pyridazin-3-on-derivative, ihre herstellung und verwendung in arzneimitteln
DE602005002470D1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
DE602005021501D1 (de) Sulfonamidderivate, ihre herstellung und ihre therapeutische anwendung
ATE479437T1 (de) Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
ATE502035T1 (de) 2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung
ATE432701T1 (de) Indol-6-sulfonamid-derivate, ihre herstellung und ihre verwendung als 5-ht-6 modulatoren
DE602004021384D1 (de) Indol-5 -sulfonamid-derivate, ihre herstellung und verwendung als 5-ht-6 modulatoren
ATE459608T1 (de) Oxopiperidinderivate, ihre herstellung und therapeutische verwendung
ATE540023T1 (de) Neuartige 3-aminoalkyl-1,3-dihydro-2h-indol-2-on- derivate, ihre herstellung und therapeutische verwendung
ATE396994T1 (de) 3-phenylpyridoindolderivate, ihre herstellung und verwendung
ATE520654T1 (de) Polypyrrol-derivate, ihre herstellung und ihre therapeutische verwendung
ATE451923T1 (de) N-(arylalkyl)-1h-pyrrolopyridin-2-carboxamid- derivate, ihre herstellung und verwendung
ATE499351T1 (de) Aryl- und heteroaryl-ethyl-acylguanidinderivate, ihre herstellung und ihre therapeutische anwendung
ATE417846T1 (de) Aminotropanderivate, deren herstellung und deren therapeutische verwendung
EP1968616A4 (de) Sulindac-derivate, ihre verwendung und herstellung
ATE542806T1 (de) Diarylmethylpiperazinderivate, deren herstellung und deren verwendung
DE602006005246D1 (de) Pyridoä2,3-düpyrimidin-derivate sowie deren herstellung und therapeutische anwendung
DE602006010337D1 (de) 1,2,4-triazinderivate, ihre herstellung und ihre verwendung in der humantherapie
ATE474840T1 (de) 6-heteroarylpyridoindolon-derivate, ihre herstellung und ihre therapeutische anwendung
DE602004024538D1 (de) Sulphonamid benzoxazinonderivate. ihre herstellung und verwendung als medikamente
ATE411295T1 (de) 2h- oder 3h-benzoäeüindazol-1-yl-karbamat- derivate, herstellung und therapeutische verwendung
DE602004021383D1 (de) Indol-7 -sulfonamid-derivate, ihre herstellung und verwendung als 5-ht-6 modulatoren
DE60304596D1 (de) In 3-position heterocyclisch substituierte pyridoindolonderivate, ihre herstellung und ihre therapeutische verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties